Even with the UK stock market near all-time highs, there are still some truly extraordinary dividend yields hiding in plain sight.
Of course, sky-high yields often signal massive risks and dividend cuts ahead. Yet occasionally, a genuinely quality business gets mispriced. And patient investors who spot it early can lock in a life-changing passive income stream.
So could Victrex (LSE:VCT) be one of those exceptions? At a 9.8% yield, the PEEK polymer specialist already stands out.
But one analyst has gone further, slapping an 870p price target on the shares. Compared to where the stock is trading today, that implies a potential 44.3% gain over the next 12 months.
So is this a screaming buy? Or is it a trap?
What does Victrex actually do?
Victrex is the world-leading manufacturer of PEEK – the high-performance polymer used in aerospace, medical devices, automotive, electronics, and energy applications. Its products are notoriously difficult to replicate, giving Victrex significant pricing power in the sectors it serves. And with over 40 years of application expertise, its moat’s real.
But if that’s the case, then why have the shares performed so poorly in recent years?
What happened?
The short answer is a painful combination of operational setbacks and structural disappointments. And the most damaging has been China.
Victrex invested heavily in a new manufacturing facility in Panjin. And what was supposed to be a major growth catalyst has so far been an underperforming headache. So much so that management has just recognised a staggering £60.6m impairment charge on the facility.
The direct hit to assets is obviously frustrating. But the more significant damage is to investor confidence. In a technically demanding industry, capital allocation skill is crucial for long-term success. And this recent escapade hasn’t exactly painted leadership in the best of light.
At the same time, underlying pre-tax profits fell 18% to £19m in H1 2026, gross margins slipped 240 basis points, and the reported loss before tax was £44m.
Can management turn it around?
To be fair, there are genuine green shoots of recovery emerging. Volume across the first half of 2026 is up by 6%, with momentum in the second quarter notably accelerating as management’s Profit Improvement plan starts to deliver some tangible savings.
That’s good news for earnings. And, crucially, the interim dividend was maintained at 13.42p per share – a strong signal of confidence that better times lie ahead.
So is this a risk worth taking?
What’s the verdict?
It’s always nice to see dividends being maintained. But when looking a little closer, it’s possible management’s digging itself deeper into a hole. Why? Because it’s taking on more debt to maintain payments to shareholders.
If volumes continue to recover and operational savings help restore profit margins, there’s likely not going to be a major issue. But if the firm fails in execution again, then not only could dividends end up on the chopping block, but the balance sheet could also become significantly more leveraged.
With that in mind, it’s no wonder why the shares are seemingly so cheap and the dividend yield so high.
Personally, the risk’s too high for my tastes. But there’s a viable road to recovery here. That’s why I’m still keeping a close eye on how Victrex performs throughout the rest of 2026.
Should you invest £5,000 in Victrex Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Victrex Plc made the list?
Zaven Boyrazian does not hold any positions in the companies mentioned.
